L. Metzinger et al., MODULATION BY PREDNISOLONE OF CALCIUM HANDLING IN SKELETAL-MUSCLE CELLS, British Journal of Pharmacology, 116(7), 1995, pp. 2811-2816
1 Increased calcium (Ca2+) influx has been incriminated as a potential
pathological mechanism in the chronic skeletal muscle degeneration ex
hibited by Duchenne muscular dystrophy (DMD) patients. We have studied
the influence of the glucocorticoid alpha-methylprednisolone (PDN), t
he only drug known to have a beneficial effect on the degenerative cou
rse of DMD, on Ca2+ handling in the C2 skeletal muscle cell line. 2 PD
N, when added 3 days (when myoblasts start to fuse into myotubes) afte
r cell seeding, led to a 2 to 4 fold decrease in cellular Ca2+ uptake.
This decrease was independent of the extracellular Ca2+ concentration
applied to cells. The effect took at least 24 h in order to become es
tablished (PDN of 10(-5) M) and took longer for lower PDN concentratio
ns (EC(50) of ca. 10(-6) M at day 5, 10(-6.5) M at day 7 and 10(-7.5)
M at day 9 in culture). 3 Cellular calcium accumulation was also decre
ased in PDN-treated myotubes exposed to Ca-45(2+)- containing medium f
or 1 to 6 days. 4 No effect of PDN was seen on Ca-45(2+) efflux; a dec
rease in the amount of Ca-45(2+) released was observed due to the redu
ction of cellular Ca-45(2+) loading. 5 PDN treatment led to an approxi
mately 2 fold decrease in basal cytosolic Ca2+ concentration. 6 Three
antioxidant drugs (lazaroids), previously shown to enhance in vitro sk
eletal muscle cell differentiation to the same extent as PDN, induced
a similar decrease in Ca2+ influx. 7 Our results suggest that long-ter
m incubation of C2 cells with PDN leads to a decrease of the size of t
he cellular Ca2+ pools and to reduced resting cytosolic Ca2+ levels. P
art of the beneficial effect of PDN in DMD patients could be attribute
d to a reduction of Ca2+ influx and of the size of Ca2+ pools in dystr
ophic muscle fibres.